Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
View original at globenewswire.comFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting ~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
There is growing interest among physicians, multidisciplinary care teams, and patients to identify strategies that may reduce long-term treatment-related toxicities and integrate these new approaches into clinical practice
60% confidenceApproximately 500,000 patients in the U.S. are diagnosed annually with cancers that could be treated with a platinum-based chemotherapy
60% confidenceOncology is undergoing a broader shift beyond tumor response alone toward prioritizing survivorship and long-term quality of life
60% confidenceThese studies represent an important step forward in addressing a critical unmet need and highlight the potential for PEDMARK to meaningfully impact patient care more broadly
60% confidencePEDMARK administration approximately 6 hours after cisplatin can be safe, easily integrated into patient care, and does not compromise cisplatin's established antitumor activity
60% confidencePEDMARK safety and efficacy has not been established when administered following cisplatin infusions longer than 6 hours
60% confidenceBetween 60-90% of patients treated with cisplatin may develop hearing loss, depending upon the dose and duration of chemotherapy
60% confidenceCisplatin-induced ototoxicity (CIO), or permanent hearing loss related to cisplatin chemotherapy, is increasingly recognized as a major survivorship issue in oncology
60% confidencePatients with hearing loss resulting from cancer treatment have a statistically significant worse quality of life compared with peers who have no hearing loss
60% confidenceAdolescent, young adult, and adult patients face a similar burden from cisplatin-induced ototoxicity but prospective data in these populations are still emerging
60% confidence